Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Adrian Harris

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Immunohistochemistry

Physiology

Anatomy

Cultured Tumor Cells

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
78
Gatter, Kevin
54
Giatromanolaki, Alexandra
53
Koukourakis, Michael
53
Turley, Helen
45
Fox, Stephen
40
Bicknell, Roy
37
Leek, Russell
35
Talbot, Denis
33
Sivridis, Efthimios
28
Kaklamanis, LG
25
Hickson, Ian
22
Pezzella, Francesco
20
Ratcliffe, Peter
20
Braybrooke, Jeremy
20
Campo, Leticia

Sign-in to see all Coauthors

Publications

TOP 3
Koukourakis Michael I; Giatromanolaki Alexandra; Sheldon Helen; Buffa Francesca M; Kouklakis George; Ragoussis Ioannis; Sivridis Efthimios; Harris Adrian L;
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
Jubb A M; Turley H; Moeller H C; Steers G; Han C; Li J-L; Leek R; Tan E Y; Singh B; Mortensen N J; Noguera-Troise I; Pezzella F; Gatter K C; Thurston G; Fox S B; Harris A L
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
Yang Jun; Ledaki Ioanna; Turley Helen; Gatter Kevin C; Montero Juan-Carlos Martinez; Li Ji-Liang; Harris Adrian L
Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Adrian Harris (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Koukourakis Michael I; Giatromanolaki Alexandra; Sheldon Helen; Buffa Francesca M; Kouklakis George; Ragoussis Ioannis; Sivridis Efthimios; Harris Adrian L;
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7069-76.
2009: Jubb A M; Turley H; Moeller H C; Steers G; Han C; Li J-L; Leek R; Tan E Y; Singh B; Mortensen N J; Noguera-Troise I; Pezzella F; Gatter K C; Thurston G; Fox S B; Harris A L
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
British journal of cancer 2009;101(10):1749-57.
2009: Yang Jun; Ledaki Ioanna; Turley Helen; Gatter Kevin C; Montero Juan-Carlos Martinez; Li Ji-Liang; Harris Adrian L
Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases.
Annals of the New York Academy of Sciences 2009;1177():185-97.
2009: Turley Helen; Steers Graham; Li Ji-Liang; Sainson Richard; Harris Adrian L; Pezzella Francesco; Gatter Kevin C
Corrigendum.
Histopathology 2009;55(4):463-4.
2009: Campbell H E; Taylor M A; Harris A L; Gray A M
An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom.
British journal of cancer 2009;101(7):1074-84.
2009: Swietach Pawel; Patiar Shalini; Supuran Claudiu T; Harris Adrian L; Vaughan-Jones Richard D
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
The Journal of biological chemistry 2009;284(30):20299-310.
2009: Milani Manuela; Rzymski Tomasz; Mellor Howard R; Pike Luke; Bottini Alberto; Generali Daniele; Harris Adrian L
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Cancer research 2009;69(10):4415-23.
2009: Martinez Juan Carlos; Müller Marcus M; Turley Helen; Steers Graham; Choteau Ludovine; Li Ji-Liang; Sainson Richard; Harris Adrian L; Pezzella Francesco; Gatter Kevin C
Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues.
Histopathology 2009;54(5):598-606.
2009: Generali Daniele; Bates Gaynor; Berruti Alfredo; Brizzi Maria P; Campo Leticia; Bonardi Simone; Bersiga Alessandra; Allevi Giovanni; Milani Manuela; Aguggini Sergio; Dogliotti Luigi; Banham Alison H; Harris Adrian L; Bottini Alberto; Fox Stephen B
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):1046-51.
2009: Tan E Y; Yan M; Campo L; Han C; Takano E; Turley H; Candiloro I; Pezzella F; Gatter K C; Millar E K A; O'Toole S A; McNeil C M; Crea P; Segara D; Sutherland R L; Harris A L; Fox S B
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
British journal of cancer 2009;100(2):405-11.
2009: Generali Daniele; Buffa Francesca M; Berruti Alfredo; Brizzi Maria P; Campo Leticia; Bonardi Simone; Bersiga Alessandra; Allevi Giovanni; Milani Manuela; Aguggini Sergio; Papotti Mauro; Dogliotti Luigi; Bottini Alberto; Harris Adrian L; Fox Stephen B
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):227-34.
2009: Li Ji-Liang; Harris Adrian L
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.
Frontiers in bioscience : a journal and virtual library 2009;14():3094-110.
2008: Giatromanolaki Alexandra; Koukourakis Michael I; Pezzella Francesco; Sivridis Efthimios; Turley Helen; Harris Adrian L; Gatter Kevin C
Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins.
Leukemia & lymphoma 2008;49(11):2181-6.
2008: Bates Gaynor J; Fox Stephen B; Han Cheng; Launchbury Rosalind; Leek Russell D; Harris Adrian L; Banham Alison H
Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
Breast cancer research and treatment 2008;111(3):453-9.
2008: Giatromanolaki Alexandra; Bates Gaynor J; Koukourakis Michael I; Sivridis Efthimios; Gatter Kevin C; Harris Adrian L; Banham Alison H
The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Gynecologic oncology 2008;110(2):216-21.
2008: Rzymski T; Paantjens A; Bod J; Harris A L
Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappaB and ATF4.
Oncogene 2008;27(33):4532-43.
2008: Wigfield S M; Winter S C; Giatromanolaki A; Taylor J; Koukourakis M L; Harris A L
PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer.
British journal of cancer 2008;98(12):1975-84.
2008: Generali D; Dovio A; Tampellini M; Tucci M; Tedoldi S; Torta M; Bonardi S; Allevi G; Aguggini S; Milani M; Harris A L; Bottini A; Dogliotti L; Angeli A; Berruti A
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
British journal of cancer 2008;98(11):1753-8.
2008: Generali Daniele; Fox Stephen B; Brizzi Maria Pia; Allevi Giovanni; Bonardi Simone; Aguggini Sergio; Milani Manuela; Bersiga Alessandra; Campo Leticia; Dionisio Rossana; Vergoni Federica; Giardini Roberto; Dogliotti Luigi; Bottini Alberto; Harris Adrian L; Berruti Alfredo
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2673-80.
2008: Lawrie Charles H; Gal Shira; Dunlop Heather M; Pushkaran Beena; Liggins Amanda P; Pulford Karen; Banham Alison H; Pezzella Francesco; Boultwood Jacqueline; Wainscoat James S; Hatton Christian S R; Harris Adrian L
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
British journal of haematology 2008;141(5):672-5.
2008: Williams Cassin Kimmel; Segarra Marta; Sierra Maria De La Luz; Sainson Richard C A; Tosato Giovanna; Harris Adrian L
Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells.
Cancer research 2008;68(6):1889-95.
2008: Harrington Laura S; Sainson Richard C A; Williams Cassin Kimmel; Taylor Jennifer M; Shi Wen; Li Ji-Liang; Harris Adrian L
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Microvascular research 2008;75(2):144-54.
2008: Shaida Nadeem; Launchbury Rosalind; Boddy Jane L; Jones Catherine; Campo Leticia; Turley Helen; Kanga Suresh; Banham Alison H; Malone Peter R; Harris Adrian L; Fox Stephen B
Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines.
The Prostate 2008;68(3):336-43.
2008: Giatromanolaki A; Koukourakis M I; Gatter K C; Harris A L; Sivridis E
BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis.
Journal of clinical pathology 2008;61(2):217-20.
2008: Sainson Richard C A; Harris Adrian L
Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies.
Angiogenesis 2008;11(1):41-51.
2007: Li Ji-Liang; Sainson Richard C A; Shi Wen; Leek Russell; Harrington Laura S; Preusser Matthias; Biswas Swethajit; Turley Helen; Heikamp Emily; Hainfellner Johannes A; Harris Adrian L
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Cancer research 2007;67(23):11244-53.
2007: Mellor Howard R; Harris Adrian L
The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer.
Cancer metastasis reviews 2007;26(3-4):553-66.
2007: Kato T; Steers G; Campo L; Roberts H; Leek R D; Turley H; Kimura T; Kameoka S; Nishikawa T; Kobayashi M; Harris A L; Gatter K C; Pezzella F
Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer.
British journal of cancer 2007;97(9):1277-86.
2007: Sainson Richard C A; Harris Adrian L
Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
Trends in molecular medicine 2007;13(9):389-95.
2007: Ord Jonathan J; Agrawal Sachin; Thamboo Thomas P; Roberts Ian; Campo Leticia; Turley Helen; Han Cheng; Fawcett Derek W; Kulkarni Ravi P; Cranston David; Harris Adrian L
An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer.
The Journal of urology 2007;178(2):677-82.
2007: Banham Alison H; Boddy Jane; Launchbury Rosalind; Han Cheng; Turley Helen; Malone Peter R; Harris Adrian L; Fox Stephen B
Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
The Prostate 2007;67(10):1091-8.
2007: Li Ji-Liang; Harris Adrian L
The potential of new tumor endothelium-specific markers for the development of antivascular therapy.
Cancer cell 2007;11(6):478-81.
2007: Rzymski Tomasz; Harris Adrian L
The unfolded protein response and integrated stress response to anoxia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2537-40.
2007: Fox Stephen B; Launchbury Rosalind; Bates Gaynor J; Han Cheng; Shaida Nadeem; Malone Peter R; Harris Adrian L; Banham Alison H
The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha.
The Prostate 2007;67(6):623-9.
2007: Winter Stuart C; Buffa Francesca M; Silva Priyamal; Miller Crispin; Valentine Helen R; Turley Helen; Shah Ketan A; Cox Graham J; Corbridge Rogan J; Homer Jarrod J; Musgrove Brian; Slevin Nick; Sloan Philip; Price Pat; West Catharine M L; Harris Adrian L
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers.
Cancer research 2007;67(7):3441-9.
2007: Generali Daniele; Fox Stephen B; Berruti Alfredo; Moore John W; Brizzi Maria Pia; Patel Nilay; Allevi Giovanni; Bonardi Simone; Aguggini Sergio; Bersiga Alessandra; Campo Leticia; Dogliotti Luigi; Bottini Alberto; Harris Adrian L
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):550-8.
2007: Tan Ern Yu; Campo Leticia; Han Cheng; Turley Helen; Pezzella Francesco; Gatter Kevin C; Harris Adrian L; Fox Stephen B
BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):467-74.
2007: Ameri K; Hammond E M; Culmsee C; Raida M; Katschinski D M; Wenger R H; Wagner E; Davis R J; Hai T; Denko N; Harris A L
Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway.
Oncogene 2007;26(2):284-9.
2007: Bacon A L; Fox S; Turley H; Harris A L
Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer.
Oncogene 2007;26(1):132-41.
2007: Tan Ern Yu; Campo Leticia; Han Cheng; Turley Helen; Pezzella Francesco; Gatter Kevin C; Harris Adrian L; Fox Stephen B
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Breast cancer research : BCR 2007;9(6):R89.
2007: Knowles Helen J; Harris Adrian L
Macrophages and the hypoxic tumour microenvironment.
Frontiers in bioscience : a journal and virtual library 2007;12():4298-314.
2006: Patiar Shalini; Harris Adrian L
Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Endocrine-related cancer 2006;13 Suppl 1():S61-75.
2006: Bates Gaynor J; Fox Stephen B; Han Cheng; Leek Russell D; Garcia José F; Harris Adrian L; Banham Alison H
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(34):5373-80.
2006: Giatromanolaki Alexandra; Sivridis Efthimios; Gatter Kevin C; Turley Helen; Harris Adrian L; Koukourakis Michael I;
Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis.
Gynecologic oncology 2006;103(3):912-8.
2006: Jones Dylan T; Pugh Christopher W; Wigfield Simon; Stevens Malcolm F G; Harris Adrian L
Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5384-94.
2006: Jones Dylan T; Harris Adrian L
Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding.
Molecular cancer therapeutics 2006;5(9):2193-202.
2006: Generali Daniele; Fox Stephen B; Berruti Alfredo; Brizzi Maria P; Campo Leticia; Bonardi Simone; Wigfield Simon M; Bruzzi Paolo; Bersiga Alessandra; Allevi Giovanni; Milani Manuela; Aguggini Sergio; Dogliotti Luigi; Bottini Alberto; Harris Adrian L
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Endocrine-related cancer 2006;13(3):921-30.
2006: Giatromanolaki A; Sivridis E; Simopoulos C; Polychronidis A; Gatter K C; Harris A L; Koukourakis M I
Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas.
Journal of surgical oncology 2006;94(3):242-7.
2006: Koukourakis Michael I; Giatromanolaki Alexandra; Sivridis Efthimios; Gatter Kevin C; Harris Adrian L;
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4301-8.
2006: Raida M; Weiss T; Leo C; Lenz D; Tarnok A; Ameri K; Harris A L; Höckel M; Niederwieser D
Circulating endothelial progenitor cells are inversely correlated with the median oxygen tension in the tumor tissue of patients with cervical cancer.
Oncology reports 2006;16(3):597-601.
2006: Koukourakis Michael I; Papazoglou Dimitrios; Giatromanolaki Alexandra; Panagopoulos Ioannis; Maltezos Efstratios; Harris Adrian L; Gatter Kevin C; Sivridis Efthimios
C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;53(3):257-62.
2006: Patel Nilay S; Dobbie Michael S; Rochester Mark; Steers Graham; Poulsom Richard; Le Monnier Karena; Cranston David W; Li Ji-Liang; Harris Adrian L
Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4836-44.
2006: Generali Daniele; Berruti Alfredo; Brizzi Maria P; Campo Leticia; Bonardi Simone; Wigfield Simon; Bersiga Alessandra; Allevi Giovanni; Milani Manuela; Aguggini Sergio; Gandolfi Valeria; Dogliotti Luigi; Bottini Alberto; Harris Adrian L; Fox Stephen B
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4562-8.
2006: Adam P J; Terrett J A; Steers G; Stockwin L; Loader J A; Fletcher G C; Lu L-S; Leach B I; Mason S; Stamps A C; Boyd R S; Pezzella F; Gatter K C; Harris A L
CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
British journal of cancer 2006;95(3):298-306.
2006: Bottini Alberto; Generali Daniele; Brizzi Maria Pia; Fox Stephen B; Bersiga Alessandra; Bonardi Simone; Allevi Giovanni; Aguggini Sergio; Bodini Giuliana; Milani Manuela; Dionisio Rossana; Bernardi Claudio; Montruccoli Arianna; Bruzzi Paolo; Harris Adrian L; Dogliotti Luigi; Berruti Alfredo
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3623-8.
2006: Winter Stuart C; Shah Ketan A; Han Cheng; Campo Leticia; Turley Helen; Leek Russell; Corbridge Rogan J; Cox Graham J; Harris Adrian L
The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.
Cancer 2006;107(4):757-66.
2006: Koukourakis Michael I; Giatromanolaki Alexandra; Polychronidis Alexandros; Simopoulos Costantinos; Gatter Kevin C; Harris Adrian L; Sivridis Efthimios
Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer.
Cancer science 2006;97(7):582-8.
2006: Giatromanolaki Alexandra; Koukourakis Michael I; Turley Helen; Sivridis Efthimios; Harris Adrian L; Gatter Kevin C;
Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006;19(5):701-7.
2006: Sainson Richard C A; Harris Adrian L
Hypoxia-regulated differentiation: let's step it up a Notch.
Trends in molecular medicine 2006;12(4):141-3.
2006: Jones Dylan T; Trowbridge Ian S; Harris Adrian L
Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate.
Cancer research 2006;66(5):2749-56.
2006: Knowles Helen J; Mole David R; Ratcliffe Peter J; Harris Adrian L
Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1.
Cancer research 2006;66(5):2600-7.
2006: Koukourakis Michael I; Bentzen Søren M; Giatromanolaki Alexandra; Wilson George D; Daley Frances M; Saunders Michele I; Dische Stanley; Sivridis Efthimios; Harris Adrian L
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(5):727-35.
2006: Knowles Helen J; te Poele Robert H; Workman Paul; Harris Adrian L
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
Biochemical pharmacology 2006;71(5):646-56.
2006: Shi Wen; Harris Adrian L
Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials.
Journal of mammary gland biology and neoplasia 2006;11(1):41-52.
2006: Koukourakis Michael I; Giatromanolaki Alexandra; Harris Adrian L; Sivridis Efthimios
Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.
Cancer research 2006;66(2):632-7.
2006: Giatromanolaki Alexandra; Koukourakis Michael I; Sivridis Efthimios; Gatter Kevin C; Harris Adrian L; Banham Alison H
Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006;19(1):9-16.
2006: Boddy Jane L; Gal Shira; Malone Peter R; Shaida Nadeem; Wainscoat James S; Harris Adrian L
The role of cell-free DNA size distribution in the management of prostate cancer.
Oncology research 2006;16(1):35-41.
2006: Cadd Verity A; Hogg Philip J; Harris Adrian L; Feller Stephan M
Molecular profiling of signalling proteins for effects induced by the anti-cancer compound GSAO with 400 antibodies.
BMC cancer 2006;6():155.
2005: Koukourakis Michael I; Giatromanolaki Alexandra; Sivridis Efthimios; Gatter Kevin C; Harris Adrian L;
Inclusion of vasculature-related variables in the Dukes staging system of colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8653-60.
2005: Smith Caroline L; Mirza Fareed; Pasquetto Valerie; Tscharke David C; Palmowski Michael J; Dunbar P Rod; Sette Alessandro; Harris Adrian L; Cerundolo Vincenzo
Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(12):8431-7.
2005: Soilleux E J; Turley H; Tian Y M; Pugh C W; Gatter K C; Harris A L
Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues.
Histopathology 2005;47(6):602-10.
2005: Boddy Jane L; Fox Stephen B; Han Cheng; Campo Leticia; Turley Helen; Kanga Suresh; Malone Peter R; Harris Adrian L
The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7658-63.
2005: Winter Stuart C; Shah Ketan A; Campo Leticia; Turley Helen; Leek Russell; Corbridge Rogan J; Cox Graham J; Harris Adrian L
Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7614-20.
2005: Kato T; Prevo R; Steers G; Roberts H; Leek R D; Kimura T; Kameoka S; Nishikawa T; Kobayashi M; Jackson D G; Harris A L; Gatter K C; Pezzella F
A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity.
British journal of cancer 2005;93(10):1168-74.
2005: Raida Martin; Clement Joachim H; Leek Russell D; Ameri Kurosh; Bicknell Roy; Niederwieser Dietger; Harris Adrian L
Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis.
Journal of cancer research and clinical oncology 2005;131(11):741-50.
2005: Patel Nilay S; Li Ji-Liang; Generali Daniele; Poulsom Richard; Cranston David W; Harris Adrian L
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Cancer research 2005;65(19):8690-7.
2005: Ord J J; Streeter E H; Roberts I S D; Cranston D; Harris A L
Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer.
British journal of cancer 2005;93(3):346-54.
2005: Li Ji-Liang; Harris Adrian L
Notch signaling from tumor cells: a new mechanism of angiogenesis.
Cancer cell 2005;8(1):1-3.
2005: Raval Raju R; Lau Kah Weng; Tran Maxine G B; Sowter Heidi M; Mandriota Stefano J; Li Ji-Liang; Pugh Christopher W; Maxwell Patrick H; Harris Adrian L; Ratcliffe Peter J
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
Molecular and cellular biology 2005;25(13):5675-86.
2005: Ord J J; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel S P; Rogers M A; Banks R E; Roberts I S D; Harris A L
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
British journal of cancer 2005;92(12):2140-7.
2005: Raida Martin; Clement Joachim H; Ameri Kurosh; Han Cheng; Leek Russell D; Harris Adrian L
Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death.
International journal of oncology 2005;26(6):1465-70.
2005: Leek Russell D; Stratford Ian; Harris Adrian L
The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway.
Cancer research 2005;65(10):4147-52.
2005: Brown N S; Streeter E H; Jones A; Harris A L; Bicknell R
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.
British journal of cancer 2005;92(9):1696-701.
2005: Williams Kaye J; Telfer Brian A; Xenaki Dia; Sheridan Mary R; Desbaillets Isabelle; Peters Hans J W; Honess Davina; Harris Adrian L; Dachs Gabi U; van der Kogel Albert; Stratford Ian J
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;75(1):89-98.
2005: Winter S C A; Corbridge R J; Cox G J; Harris A L
Hypoxia and anaemia in head and neck squamous cell carcinoma - mechanisms of therapy failure and provision of new therapeutic targets.
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2005;30(2):99-104.
2005: Campo Leticia; Turley Helen; Han Cheng; Pezzella Francesco; Gatter Kevin C; Harris Adrian L; Fox Stephen B
Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival.
The Journal of pathology 2005;205(5):585-91.
2005: Carroll Veronica A; Nikitenko Leonid L; Bicknell Roy; Harris Adrian L
Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(4):736-41.
2005: Caine G J; Harris A L; Christodoulos K; Lip G Y H; Blann A D
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Cancer letters 2005;219(2):163-7.
2005: Braybrooke Jeremy P; Slade Andrew; Deplanque Gael; Harrop Richard; Madhusudan Srinivasan; Forster Martin D; Gibson Rachel; Makris Andreas; Talbot Denis C; Steiner Jan; White Linda; Kan On; Naylor Stuart; Carroll Miles W; Kingsman Sue M; Harris Adrian L
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1512-20.
2005: Boddy Jane L; Gal Shira; Malone Peter R; Harris Adrian L; Wainscoat Jim S
Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1394-9.
2005: Pillai G; Cook N; Turley H; Leek R D; Blasquez C; Pezzella F; Harris A L; Gatter K C
The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study.
Histopathology 2005;46(2):209-16.
2005: Vleugel M M; Greijer A E; Shvarts A; van der Groep P; van Berkel M; Aarbodem Y; van Tinteren H; Harris A L; van Diest P J; van der Wall E
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.
Journal of clinical pathology 2005;58(2):172-7.
2005: Koukourakis Michael I; Giatromanolaki Alexandra; Sivridis Efthimios; Gatter Kevin C; Harris Adrian L;
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma.
Neoplasia (New York, N.Y.) 2005;7(1):1-6.
2005: Smith Caroline L; Dunbar P Rod; Mirza Fareed; Palmowski Michael J; Shepherd Dawn; Gilbert Sarah C; Coulie Pierre; Schneider Joerg; Hoffman Eric; Hawkins Robert; Harris Adrian L; Cerundolo Vincenzo
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
International journal of cancer. Journal international du cancer 2005;113(2):259-66.
2004: Hutchison Gillian J; Valentine Helen R; Loncaster Juliette A; Davidson Susan E; Hunter Robert D; Roberts Stephen A; Harris Adrian L; Stratford Ian J; Price Patricia M; West Catharine M L
Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8405-12.
2004: Silk Jonathan D; Hermans Ian F; Gileadi Uzi; Chong Tsung Wen; Shepherd Dawn; Salio Mariolina; Mathew Bini; Schmidt Richard R; Lunt Sarah Jane; Williams Kaye J; Stratford Ian J; Harris Adrian L; Cerundolo Vincenzo
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
The Journal of clinical investigation 2004;114(12):1800-11.
2004: Deplanque G; Madhusudan S; Jones P H; Wellmann S; Christodoulos K; Talbot D C; Ganesan T S; Blann A; Harris A L
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
British journal of cancer 2004;91(9):1645-50.
2004: Madhusudan Srinivasan; Foster Martin; Muthuramalingam Sethupathi R; Braybrooke Jeremy P; Wilner Susan; Kaur Kulwinder; Han Cheng; Hoare Susan; Balkwill Frances; Talbot Denis C; Ganesan Trivadi S; Harris Adrian L
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6528-34.
2004: Knies-Bamforth Ulrike E; Fox Stephen B; Poulsom Richard; Evan Gerard I; Harris Adrian L
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Cancer research 2004;64(18):6563-70.
2004: Robertson Naomi; Potter Christian; Harris Adrian L
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Cancer research 2004;64(17):6160-5.
2004: Fox Stephen B; Bragança José; Turley Helen; Campo Leticia; Han Cheng; Gatter Kevin C; Bhattacharya Shoumo; Harris Adrian L
CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha.
Cancer research 2004;64(17):6075-81.
2004: Appelhoff Rebecca J; Tian Ya-Min; Raval Raju R; Turley Helen; Harris Adrian L; Pugh Christopher W; Ratcliffe Peter J; Gleadle Jonathan M
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.
The Journal of biological chemistry 2004;279(37):38458-65.
2004: Chakrabarti J; Turley H; Campo L; Han C; Harris A L; Gatter K C; Fox S B
The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers.
British journal of cancer 2004;91(5):954-8.
2004: Fox Stephen B; Harris Adrian L
Histological quantitation of tumour angiogenesis.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2004;112(7-8):413-30.
2004: Turley Helen; Wykoff Charles C; Troup Sandra; Watson Peter H; Gatter Kevin C; Harris Adrian L
The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours.
The Journal of pathology 2004;203(3):808-13.
2004: Knowles Helen J; Tian Ya-Min; Mole David R; Harris Adrian L
Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
Circulation research 2004;95(2):162-9.
2004: Jones P H; Christodoulos K; Dobbs N; Thavasu P; Balkwill F; Blann A D; Caine G J; Kumar S; Kakkar A J; Gompertz N; Talbot D C; Ganesan T S; Harris A L
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
British journal of cancer 2004;91(1):30-6.
2004: Fox Stephen B; Brown Philip; Han Cheng; Ashe Sally; Leek Russel D; Harris Adrian L; Banham Alison H
Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3521-7.
2004: Koukourakis Michael I; Giatromanolaki Alexandra; Sivridis Efthimios; Pastorek Jaromir; Karapantzos Ilias; Gatter Kevin C; Harris Adrian L;
Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
International journal of radiation oncology, biology, physics 2004;59(1):67-71.
2004: Wykoff C C; Sotiriou C; Cockman M E; Ratcliffe P J; Maxwell P; Liu E; Harris A L
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene.
British journal of cancer 2004;90(6):1235-43.
2004: Gal S; Fidler C; Lo Y M D; Taylor M; Han C; Moore J; Harris A L; Wainscoat J S
Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR.
British journal of cancer 2004;90(6):1211-5.
2004: Ripley Ruth M; Harris Adrian L; Tarassenko Lionel
Non-linear survival analysis using neural networks.
Statistics in medicine 2004;23(5):825-42.
2004: Ameri Kurosh; Lewis Claire E; Raida Martin; Sowter Heidi; Hai Tsonwin; Harris Adrian L
Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells.
Blood 2004;103(5):1876-82.
2004: Madhusudan Srinivasan; Deplanque Gaël; Braybrooke Jeremy P; Cattell Emma; Taylor Marian; Price Pat; Tsaloumas Marie D; Moore Niall; Huson Susan M; Adams Chris; Frith Peggy; Scigalla Paul; Harris Adrian L
Antiangiogenic therapy for von Hippel-Lindau disease.
JAMA : the journal of the American Medical Association 2004;291(8):943-4.
2004: Potter Christian; Harris Adrian L
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Cell cycle (Georgetown, Tex.) 2004;3(2):164-7.
2004: Bacon Andrea L; Harris Adrian L
Hypoxia-inducible factors and hypoxic cell death in tumour physiology.
Annals of medicine 2004;36(7):530-9.
2004: Knowles Helen; Leek Russell; Harris Adrian L
Macrophage infiltration and angiogenesis in human malignancy.
Novartis Foundation symposium 2004;256():189-200; discussion 200-4, 259-69.
2004: Bicknell Roy; Harris Adrian L
Novel angiogenic signaling pathways and vascular targets.
Annual review of pharmacology and toxicology 2004;44():219-38.
2003: Hermans Ian F; Chong Tsung Wen; Palmowski Michael J; Harris Adrian L; Cerundolo Vincenzo
Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Cancer research 2003;63(23):8408-13.
2003: Sowter Heidi Michelle; Ferguson Mary; Pym Caroline; Watson Peter; Fox Stephen B; Han Cheng; Harris Adrian L
Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade.
The Journal of pathology 2003;201(4):573-80.
2003: Hermans Ian F; Silk Jonathan D; Gileadi Uzi; Salio Mariolina; Mathew Bini; Ritter Gerd; Schmidt Richard; Harris Adrian L; Old Lloyd; Cerundolo Vincenzo
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(10):5140-7.
2003: Braybrooke Jeremy P; Levitt Nicola C; Joel Simon; Davis Theresa; Madhusudan Srinivasan; Turley Helen; Wilner Sue; Harris Adrian L; Talbot Denis C
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4682-8.
2003: Madhusudan S; Protheroe A; Propper D; Han C; Corrie P; Earl H; Hancock B; Vasey P; Turner A; Balkwill F; Hoare S; Harris A L
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.
British journal of cancer 2003;89(8):1418-22.
2003: Sowter Heidi M; Raval Raju R; Moore John W; Ratcliffe Peter J; Harris Adrian L
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia.
Cancer research 2003;63(19):6130-4.
2003: Han C; Braybrooke J P; Deplanque G; Taylor M; Mackintosh D; Kaur K; Samouri K; Ganesan T S; Harris A L; Talbot D C
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
British journal of cancer 2003;89(7):1166-71.
2003: Adam Paul J; Berry Joanne; Loader Julie A; Tyson Kerry L; Craggs Graham; Smith Paul; De Belin Jackie; Steers Graham; Pezzella Francesco; Sachsenmeir Kris F; Stamps Alasdair C; Herath Athula; Sim Edith; O'Hare Michael J; Harris Adrian L; Terrett Jonathan A
Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro.
Molecular cancer research : MCR 2003;1(11):826-35.
2003: Marsh H P; Haldar N A; Bunce M; Marshall S E; le Monier K; Winsey S L; Christodoulos K; Cranston D; Welsh K I; Harris A L
Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation.
British journal of cancer 2003;89(6):1096-101.
2003: Koukourakis M I; Giatromanolaki A; Sivridis E; Bougioukas G; Didilis V; Gatter K C; Harris A L;
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.
British journal of cancer 2003;89(5):877-85.
2003: Potter C P S; Harris A L
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.
British journal of cancer 2003;89(1):2-7.
2003: Stewart M; Turley H; Cook N; Pezzella F; Pillai G; Ogilvie D; Cartlidge S; Paterson D; Copley C; Kendrew J; Barnes C; Harris A L; Gatter K C
The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study.
Histopathology 2003;43(1):33-9.
2003: Chinje Edwin C; Cowen Rachel L; Feng Jian; Sharma Sanjeev P; Wind Natasha S; Harris Adrian L; Stratford Ian J
Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Molecular pharmacology 2003;63(6):1248-55.
2003: Williams Cory S M; Leek Russell D; Robson Alistair M; Banerji Suneale; Prevo Remko; Harris Adrian L; Jackson David G
Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer.
The Journal of pathology 2003;200(2):195-206.
2003: Kuenen Bart C; Tabernero Jose; Baselga Jose; Cavalli Franco; Pfanner Elisabeth; Conte Pier Franco; Seeber Siegfried; Madhusudan Srinivasan; Deplanque Gael; Huisman Holgen; Scigalla Paul; Hoekman Klaas; Harris Adrian L
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1648-55.
2003: Knowles Helen J; Raval Raju R; Harris Adrian L; Ratcliffe Peter J
Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells.
Cancer research 2003;63(8):1764-8.
2003: Watson P H; Chia S K; Wykoff C C; Han C; Leek R D; Sly W S; Gatter K C; Ratcliffe P; Harris A L
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma.
British journal of cancer 2003;88(7):1065-70.
2003: Giatromanolaki A; Sivridis E; Maltezos E; Papazoglou D; Simopoulos C; Gatter K C; Harris A L; Koukourakis M I
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.
Journal of clinical pathology 2003;56(3):209-13.
2003: Airley Rachel E; Loncaster Juliette; Raleigh James A; Harris Adrian L; Davidson Susan E; Hunter Robert D; West Catharine M L; Stratford Ian J
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
International journal of cancer. Journal international du cancer 2003;104(1):85-91.
2003: Fletcher G C; Patel S; Tyson K; Adam P J; Schenker M; Loader J A; Daviet L; Legrain P; Parekh R; Harris A L; Terrett J A
hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan.
British journal of cancer 2003;88(4):579-85.
2003: Adam Paul J; Boyd Robert; Tyson Kerry L; Fletcher Graham C; Stamps Alasdair; Hudson Lindsey; Poyser Helen R; Redpath Nick; Griffiths Matthew; Steers Graham; Harris Adrian L; Patel Sonal; Berry Joanne; Loader Julie A; Townsend R Reid; Daviet Laurent; Legrain Pierre; Parekh Raj; Terrett Jonathan A
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer.
The Journal of biological chemistry 2003;278(8):6482-9.
2003: Propper David J; Chao David; Braybrooke Jeremy P; Bahl Pru; Thavasu Parames; Balkwill Frances; Turley Helen; Dobbs Nicola; Gatter Kevin; Talbot Denis C; Harris Adrian L; Ganesan Trivadi S
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):84-92.
2003: Winters Zoë E; Leek Russell D; Bradburn Mike J; Norbury Chris J; Harris Adrian L
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis.
Breast cancer research : BCR 2003;5(6):R242-9.
2003: Giatromanolaki Alexandra; Sivridis Efthimios; Maltezos Efstratios; Athanassou Nick; Papazoglou Dimitrios; Gatter Kevin C; Harris Adrian L; Koukourakis Michael I
Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis.
Arthritis research & therapy 2003;5(4):R193-201.
2002: Adeyinka Adewale; Emberley Ethan; Niu Yulian; Snell Linda; Murphy Leigh C; Sowter Heidi; Wykoff Charles C; Harris Adrian L; Watson Peter H
Analysis of gene expression in ductal carcinoma in situ of the breast.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3788-95.
2002: Chong Tsung Wen; Horwitz Lawrence D; Moore John W; Sowter Heidi M; Harris Adrian L
A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Cancer research 2002;62(23):6924-7.
2002: Wilson Katherine S; Roberts Helen; Leek Russell; Harris Adrian L; Geradts Joseph
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.
The American journal of pathology 2002;161(4):1171-85.
2002: Goonewardene T I; Sowter H M; Harris A L
Hypoxia-induced pathways in breast cancer.
Microscopy research and technique 2002;59(1):41-8.
2002: Sivridis Efthimios; Giatromanolaki Alexandra; Gatter Kevin C; Harris Adrian L; Koukourakis Michael I;
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Cancer 2002;95(5):1055-63.
2002: Koukourakis Michael I; Giatromanolaki Alexandra; Sivridis Efthimios; Simopoulos Constantinos; Turley Helen; Talks Kate; Gatter Kevin C; Harris Adrian L
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.
International journal of radiation oncology, biology, physics 2002;53(5):1192-202.
2002: Madhusudan Srinivasan; Harris Adrian L
Drug inhibition of angiogenesis.
Current opinion in pharmacology 2002;2(4):403-14.
2002: Mandriota Stefano J; Turner Kevin J; Davies David R; Murray Paul G; Morgan Neil V; Sowter Heidi M; Wykoff Charles C; Maher Eamonn R; Harris Adrian L; Ratcliffe Peter J; Maxwell Patrick H
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
Cancer cell 2002;1(5):459-68.
2002: Streeter Edward H; Harris Adrian L
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Surgical oncology 2002;11(1-2):85-100.
2002: Turner Kevin J; Moore John W; Jones Adam; Taylor Claire F; Cuthbert-Heavens Darren; Han Cheng; Leek Russell D; Gatter Kevin C; Maxwell Patrick H; Ratcliffe Peter J; Cranston David; Harris Adrian L
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Cancer research 2002;62(10):2957-61.
2002: Sivridis E; Giatromanolaki A; Papadopoulos I; Gatter K C; Harris A L; Koukourakis M I
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
British journal of cancer 2002;86(9):1465-71.
2002: Beasley Nigel J P; Leek Russell; Alam Mohammed; Turley Helen; Cox Graham J; Gatter Kevin; Millard Peter; Fuggle Sue; Harris Adrian L
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients.
Cancer research 2002;62(9):2493-7.
2002: Leek Russell D; Harris Adrian L
Tumor-associated macrophages in breast cancer.
Journal of mammary gland biology and neoplasia 2002;7(2):177-89.
2002: Turner K J; Crew J P; Wykoff C C; Watson P H; Poulsom R; Pastorek J; Ratcliffe P J; Cranston D; Harris A L
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
British journal of cancer 2002;86(8):1276-82.
2002: Sivridis Efthimios; Giatromanolaki Alexandra; Anastasiadis Panagiotis; Georgiou Loukas; Gatter Kevin C; Harris Adrian L; Bicknell Roy; Koukourakis Michael I;
Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
The Journal of pathology 2002;196(4):416-22.
2002: Leek Russell D; Talks Kate L; Pezzella Francesco; Turley Helen; Campo Leticia; Brown Nicholas S; Bicknell Roy; Taylor Marian; Gatter Kevin C; Harris Adrian L
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Cancer research 2002;62(5):1326-9.
2002: Beasley Nigel J P; Prevo Remko; Banerji Suneale; Leek Russell D; Moore John; van Trappen Philippe; Cox Graham; Harris Adrian L; Jackson David G
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer.
Cancer research 2002;62(5):1315-20.
2002: Jones Adam; Fujiyama Chisato; Turner Kevin; Cranston David; Williams Kaye; Stratford Ian; Bicknell Roy; Harris Adrian L
Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
The Journal of urology 2002;167(3):1482-6.
2002: Harris Adrian L
Hypoxia--a key regulatory factor in tumour growth.
Nature reviews. Cancer 2002;2(1):38-47.
2002: Williams Kaye J; Telfer Brian A; Airley Rachel E; Peters Hans P W; Sheridan Mary R; van der Kogel Albert J; Harris Adrian L; Stratford Ian J
A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis.
Oncogene 2002;21(2):282-90.
2001: Pezzella F; Harris A L; Gatter K C
Ways of escape: are all tumours angiogenic?
Histopathology 2001;39(6):551-3.
2001: Winters Z E; Hunt N C; Bradburn M J; Royds J A; Turley H; Harris A L; Norbury C J
Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2405-12.
2001: Giatromanolaki A; Harris A L
Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer.
Anticancer research 2001;21(6B):4317-24.
2001: Kakolyris S; Giatromanolaki A; Koukourakis M; Kaklamanis L; Kouroussis C H; Bozionelou V; Georgoulias V; Gatter K C; Harris A L
Assessment of vascular maturation in lung and breast carcinomas using a novel basement membrane component, LH39.
Anticancer research 2001;21(6B):4311-6.
2001: Giatromanolaki A; Sivridis E; Brekken R; Thorpe P E; Anastasiadis P; Gatter K C; Harris A L; Koukourakis M I;
The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications.
Cancer 2001;92(10):2569-77.
2001: Mackay H J; McInnes A; Paul J; Raby N; Lofts F J; McDonald A C; Soukop M; Fullarton G M; Harris A L; Garcia-Vargas J; Evans T R
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1407-10.
2001: Blancher C; Moore J W; Robertson N; Harris A L
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Cancer research 2001;61(19):7349-55.
2001: Gal S; Fidler C; Lo Y M; Chin K; Moore J; Harris A L; Wainscoat J S
Detection of mammaglobin mRNA in the plasma of breast cancer patients.
Annals of the New York Academy of Sciences 2001;945():192-4.
2001: Sowter H M; Ratcliffe P J; Watson P; Greenberg A H; Harris A L
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors.
Cancer research 2001;61(18):6669-73.
2001: Giatromanolaki A; Koukourakis M I; Sivridis E; Turley H; Talks K; Pezzella F; Gatter K C; Harris A L
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
British journal of cancer 2001;85(6):881-90.
2001: Chia S K; Wykoff C C; Watson P H; Han C; Leek R D; Pastorek J; Gatter K C; Ratcliffe P; Harris A L
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(16):3660-8.
2001: Harris A L; Reusch P; Barleon B; Hang C; Dobbs N; Marme D
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1992-7.
2001: Levitt N C; Eskens F A; O'Byrne K J; Propper D J; Denis L J; Owen S J; Choi L; Foekens J A; Wilner S; Wood J M; Nakajima M; Talbot D C; Steward W P; Harris A L; Verweij J
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1912-22.
2001: Beasley N J; Wykoff C C; Watson P H; Leek R; Turley H; Gatter K; Pastorek J; Cox G J; Ratcliffe P; Harris A L
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Cancer research 2001;61(13):5262-7.
2001: Clarke K; Smith K; Gullick W J; Harris A L
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.
British journal of cancer 2001;84(10):1322-9.
2001: Jones A; Fujiyama C; Blanche C; Moore J W; Fuggle S; Cranston D; Bicknell R; Harris A L
Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1263-72.
2001: Giatromanolaki A; Sivridis E; Athanassou N; Zois E; Thorpe P E; Brekken R A; Gatter K C; Harris A L; Koukourakis I M; Koukourakis M I
The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
The Journal of pathology 2001;194(1):101-8.
2001: Koukourakis M I; Giatromanolaki A; Kakolyris S; Sivridis E; Georgoulias V; Funtzilas G; Hickson I D; Gatter K C; Harris A L
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome.
International journal of radiation oncology, biology, physics 2001;50(1):27-36.
2001: Wykoff C C; Beasley N; Watson P H; Campo L; Chia S K; English R; Pastorek J; Sly W S; Ratcliffe P; Harris A L
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
The American journal of pathology 2001;158(3):1011-9.
2001: Propper D J; McDonald A C; Man A; Thavasu P; Balkwill F; Braybrooke J P; Caponigro F; Graf P; Dutreix C; Blackie R; Kaye S B; Ganesan T S; Talbot D C; Harris A L; Twelves C
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1485-92.
2001: Huminiecki L; Chan H Y; Lui S; Poulsom R; Stamp G; Harris A L; Bicknell R
Vascular endothelial growth factor transgenic mice exhibit reduced male fertility and placental rejection.
Molecular human reproduction 2001;7(3):255-64.
2001: Fujiyama C; Jones A; Fuggle S; Bicknell R; Cranston D; Harris A L
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
British journal of cancer 2001;84(4):558-64.
2001: Wykoff C C; Pugh C W; Harris A L; Maxwell P H; Ratcliffe P J
The HIF pathway: implications for patterns of gene expression in cancer.
Novartis Foundation symposium 2001;240():212-25; discussion 225-31.
2001: Knowles H J; Harris A L
Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis.
Breast cancer research : BCR 2001;3(5):318-22.
2000: Wykoff C C; Pugh C W; Maxwell P H; Harris A L; Ratcliffe P J
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Oncogene 2000;19(54):6297-305.
2000: Blancher C; Moore J W; Talks K L; Houlbrook S; Harris A L
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines.
Cancer research 2000;60(24):7106-13.
2000: Wykoff C C; Beasley N J; Watson P H; Turner K J; Pastorek J; Sibtain A; Wilson G D; Turley H; Talks K L; Maxwell P H; Pugh C W; Ratcliffe P J; Harris A L
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Cancer research 2000;60(24):7075-83.
2000: Braybrooke J P; O'Byrne K J; Propper D J; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan T S; Talbot D C; Harris A L
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4697-704.
2000: Dunbar P R; Smith C L; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris A L; Cerundolo V
A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(11):6644-52.
2000: Brown N S; Jones A; Fujiyama C; Harris A L; Bicknell R
Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.
Cancer research 2000;60(22):6298-302.
2000: Winsey S L; Haldar N A; Marsh H P; Bunce M; Marshall S E; Harris A L; Wojnarowska F; Welsh K I
A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer.
Cancer research 2000;60(20):5612-6.
2000: Giatromanolaki A; Koukourakis M I; Sivridis E; O'Byrne K; Gatter K C; Harris A L
'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer.
The Journal of pathology 2000;192(2):140-9.
2000: Sivridis E; Giatromanolaki A; Koukourakis M I; Bicknell R; Harris A L; Gatter K C
Thymidine phosphorylase expression in normal and hyperplastic endometrium.
Journal of clinical pathology 2000;53(9):704-8.
2000: Deplanque G; Harris A L
Anti-angiogenic agents: clinical trial design and therapies in development.
European journal of cancer (Oxford, England : 1990) 2000;36(13 Spec No):1713-24.
2000: Talks K L; Turley H; Gatter K C; Maxwell P H; Pugh C W; Ratcliffe P J; Harris A L
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.
The American journal of pathology 2000;157(2):411-21.
2000: Braybrooke J P; Propper D J; O'Byrne K J; Koukourakis M I; Patterson A V; Houlbrook S; Love S D; Varcoe S; Taylor M; Ganesan T S; Talbot D C; Harris A L
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
British journal of cancer 2000;83(2):219-24.
2000: Jones A; Fujiyama C; Turner K; Fuggle S; Cranston D; Turley H; Valtola R; Bicknell R; Harris A L
Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis.
BJU international 2000;86(1):80-6.
2000: Zhang H T; Scott P A; Morbidelli L; Peak S; Moore J; Turley H; Harris A L; Ziche M; Bicknell R
The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo.
British journal of cancer 2000;83(1):63-8.
2000: Talks K L; Harris A L
Current status of antiangiogenic factors.
British journal of haematology 2000;109(3):477-89.
2000: Koukourakis M I; Giatromanolaki A; Thorpe P E; Brekken R A; Sivridis E; Kakolyris S; Georgoulias V; Gatter K C; Harris A L
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.
Cancer research 2000;60(11):3088-95.
2000: O'Byrne K J; Dobbs N; Harris A L
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients.
British journal of cancer 2000;82(11):1895-6.
2000: Propper D J; Levitt N C; O'Byrne K; Braybrooke J P; Talbot D C; Ganesan T S; Thompson C H; Rajagopalan B; Littlewood T J; Dixon R M; Harris A L
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
British journal of cancer 2000;82(11):1776-82.
2000: Propper D J; Braybrooke J P; Levitt N C; O'Byrne K; Christodoulos K; Han C; Talbot D C; Ganesan T S; Harris A L
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
British journal of cancer 2000;82(11):1759-63.
2000: Giatromanolaki A; Koukourakis M I; Sivridis E; O'Byrne K; Cox G; Thorpe P E; Gatter K C; Harris A L
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1917-21.
2000: Wang S W; Toda T; MacCallum R; Harris A L; Norbury C
Cid1, a fission yeast protein required for S-M checkpoint control when DNA polymerase delta or epsilon is inactivated.
Molecular and cellular biology 2000;20(9):3234-44.
2000: Saunders M P; Jaffar M; Patterson A V; Nolan J; Naylor M A; Phillips R M; Harris A L; Stratford I J
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.
Biochemical pharmacology 2000;59(8):993-6.
2000: Leek R D; Hunt N C; Landers R J; Lewis C E; Royds J A; Harris A L
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer.
The Journal of pathology 2000;190(4):430-6.
2000: Kakolyris S; Fox S B; Koukourakis M; Giatromanolaki A; Brown N; Leek R D; Taylor M; Leigh I M; Gatter K C; Harris A L
Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.
British journal of cancer 2000;82(4):844-51.
2000: Eskens F A; Levitt N C; Sparreboom A; Choi L; Mather R; Verweij J; Harris A L
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):431-3.
2000: Saunders M P; Patterson A V; Chinje E C; Harris A L; Stratford I J
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
British journal of cancer 2000;82(3):651-6.
2000: Jones A; Fujiyama C; Turner K; Fuggle S; Cranston D; Bicknell R; Harris A L
Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.
BJU international 2000;85(3):276-80.
2000: Koukourakis M I; Giatromanolaki A; Guddo F; Kaklamanis L; Vignola M; Kakolyris S; Turley H; Georgoulias V; Bonsignore G; Gatter K C; Harris A L
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):104-14.
2000: Giatromanolaki A; Koukourakis M I; Sivridis E; Thorpe P E; Brekken R A; Konstantinos S; Fountzilas G; Gatter K C; Harris A L
Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.
Clinical & experimental metastasis 2000;18(4):313-9.
2000: Kakolyris S A; Kaklamanis L G; Koukourakis M J; Giatromanolaki A; Rousomoustakaki M; Souglakos J C; Reppa D K; Georgoulias V A; Gatter K C; Harris A L
Angiogenesis and p53 expression in the colorectal adenoma-carcinoma sequence.
Oncology research 2000;12(4):203-8.
2000: Kaklamanis L; Kakolyris S; Koukourakis M; Gatter K C; Harris A L
From hyperplasia to neoplasia and invasion: angiogenesis in the colorectal adenoma-carcinoma model.
Advances in experimental medicine and biology 2000;476():249-66.
2000: Braybrooke J P; Vallis K A; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan T S; Harris A L; Talbot D C
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Cancer chemotherapy and pharmacology 2000;46(1):27-34.
2000: Harris A L
von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
The oncologist 2000;5 Suppl 1():32-6.
2000: Braybrooke J P; Houlbrook S; Crawley J E; Propper D J; O'Byrne K J; Stratford I J; Harris A L; Shuker D E; Talbot D C
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Cancer chemotherapy and pharmacology 2000;45(2):111-9.
1999: Chinje E C; Patterson A V; Saunders M P; Lockyer S D; Harris A L; Stratford I J
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
British journal of cancer 1999;81(7):1127-33.
1999: Kakolyris S; Giatromanolaki A; Koukourakis M; Leigh I M; Georgoulias V; Kanavaros P; Sivridis E; Gatter K C; Harris A L
Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression.
Cancer research 1999;59(21):5602-7.
1999: Kakolyris S; Giatromanolaki A; Koukourakis M; Kaklamanis L; Kanavaros P; Hickson I D; Barzilay G; Georgoulias V; Gatter K C; Harris A L
Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC).
The Journal of pathology 1999;189(3):351-7.
1999: Smith K; Bui T D; Poulsom R; Kaklamanis L; Williams G; Harris A L
Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer.
British journal of cancer 1999;81(3):496-502.
1999: O'Byrne K J; Philip P A; Propper D J; Braybrooke J P; Saunders M P; Bates N P; Taylor M A; Madigan D; Ganesan T S; Talbot D C; Harris A L
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):981-3.
1999: Propper D J; Braybrooke J P; Taylor D J; Lodi R; Styles P; Cramer J A; Collins W C; Levitt N C; Talbot D C; Ganesan T S; Harris A L
Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):923-7.
1999: Sivridis E; Giatromanolaki A; Koukourakis M I; Bicknell R; Harris A L; Gatter K C
Thymidine phosphorylase expression in endometrial carcinomas.
Clinical & experimental metastasis 1999;17(5):445-50.
1999: Propper D J; Saunders M P; Salisbury A J; Long L; O'Byrne K J; Braybrooke J P; Dowsett M; Taylor M; Talbot D C; Ganesan T S; Harris A L
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1682-9.
1999: Smith K; Fox S B; Whitehouse R; Taylor M; Greenall M; Clarke J; Harris A L
Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):707-13.
1999: O'Byrne K J; Dobbs N; Propper D; Smith K; Harris A L
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer.
Lancet 1999;353(9163):1494-5.
1999: O'Byrne K J; Dobbs N; Propper D J; Braybrooke J P; Koukourakis M I; Mitchell K; Woodhull J; Talbot D C; Schally A V; Harris A L
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
British journal of cancer 1999;79(9-10):1413-8.
1999: Macaulay V M; O'Byrne K J; Saunders M P; Braybrooke J P; Long L; Gleeson F; Mason C S; Harris A L; Brown P; Talbot D C
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):513-20.
1999: Crew J P; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris A L
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
The Journal of urology 1999;161(3):799-804.
1999: Leek R D; Landers R J; Harris A L; Lewis C E
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast.
British journal of cancer 1999;79(5-6):991-5.
1999: Koukourakis M I; Giatromanolaki A; O'Byrne K J; Cox J; Krammer B; Gatter K C; Harris A L
bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.
Clinical & experimental metastasis 1999;17(7):545-54.
1999: Giatromanolaki A; Sivridis E; Koukourakis M I; Georgoulias V; Gatter K C; Harris A L
Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas?
Oncology research 1999;11(4):205-12.
1999: Philip P A; Rea D; Mitchell K; Carmichael J; Harris A L; Talbot D C
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1999;11(2):84-9.
1998: Kakolyris S; Kaklamanis L; Giatromanolaki A; Koukourakis M; Hickson I D; Barzilay G; Turley H; Leek R D; Kanavaros P; Georgoulias V; Gatter K C; Harris A L
Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human disease.
Histopathology 1998;33(6):561-9.
1998: Giatromanolaki A; Koukourakis M I; Kakolyris S; Turley H; O'Byrne K; Scott P A; Pezzella F; Georgoulias V; Harris A L; Gatter K C
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(12):3017-24.
1998: Turley H; Scott P A; Watts V M; Bicknell R; Harris A L; Gatter K C
Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1.
The Journal of pathology 1998;186(3):313-8.
1998: Propper D J; Macaulay V; O'Byrne K J; Braybrooke J P; Wilner S M; Ganesan T S; Talbot D C; Harris A L
A phase II study of bryostatin 1 in metastatic malignant melanoma.
British journal of cancer 1998;78(10):1337-41.
1998: Wiesener M S; Turley H; Allen W E; Willam C; Eckardt K U; Talks K L; Wood S M; Gatter K C; Harris A L; Pugh C W; Ratcliffe P J; Maxwell P H
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.
Blood 1998;92(7):2260-8.
1998: Guddo F; Giatromanolaki A; Koukourakis M I; Reina C; Vignola A M; Chlouverakis G; Hilkens J; Gatter K C; Harris A L; Bonsignore G
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.
Journal of clinical pathology 1998;51(9):667-71.
1998: Giatromanolaki A; Sivridis E; Koukourakis M I; Harris A L; Gatter K C
Bcl-2 and p53 expression in stage I endometrial carcinoma.
Anticancer research 1998;18(5B):3689-93.
1998: O'Byrne K J; Han C; Mitchell K; Lane D; Carmichael J; Harris A L; Talbot D C
Phase II study of liarozole in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1463-6.
1998: Zhang L; Scott P A; Turley H; Leek R; Lewis C E; Gatter K C; Harris A L; Mackenzie I Z; Rees M C; Bicknell R
Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium.
The Journal of pathology 1998;185(4):402-8.
1998: Winters Z E; Ongkeko W M; Harris A L; Norbury C J
p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells.
Oncogene 1998;17(6):673-84.
1998: Jones A; Harris A L
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
The cancer journal from Scientific American 1998;4(4):209-17.
1998: Patterson A V; Talbot D C; Stratford I J; Harris A L
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Cancer research 1998;58(13):2737-40.
1998: Blancher C; Harris A L
The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target.
Cancer metastasis reviews 1998;17(2):187-94.
1998: Macaulay V M; O'Byrne K J; Green J A; Philip P A; McKinley L; LaCreta F P; Winograd B; Ganesan T S; Harris A L; Talbot D C
Phase I study of the mitomycin C analogue BMS-181174.
British journal of cancer 1998;77(11):2020-7.
1998: O'Byrne K J; Koukourakis M I; Saunders M P; Salisbury A J; Isaacs R; Varcoe S; Taylor M; Ganesan T S; Harris A L; Talbot D C
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
British journal of cancer 1998;77(11):1950-6.
1998: Kaklamanis L; Savage A; Whitehouse R; Doussis-Anagnostopoulou I; Biddolph S; Tsiotos P; Mortensen N; Gatter K C; Harris A L
Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer.
British journal of cancer 1998;77(11):1864-9.
1998: Leek R D; Landers R; Fox S B; Ng F; Harris A L; Lewis C E
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
British journal of cancer 1998;77(12):2246-51.
1998: Scott P A; Smith K; Poulsom R; De Benedetti A; Bicknell R; Harris A L
Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.
British journal of cancer 1998;77(12):2120-8.
1998: Harris A L
Are angiostatin and endostatin cures for cancer?
Lancet 1998;351(9116):1598-9.
1998: Kakolyris S; Kaklamanis L; Engels K; Fox S B; Taylor M; Hickson I D; Gatter K C; Harris A L
Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis.
British journal of cancer 1998;77(7):1169-73.
1998: Giatromanolaki A; Koukourakis M I; Kakolyris S; Kaklamanis L; Barbatis K; O'Byrne K J; Theodosssiou D; Harris A L; Gatter K C
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer.
Anticancer research 1998;18(1A):71-6.
1998: Kaklamanis L; Kakolyris S; Turley H; Koukourakis M; Biddolph S; Gatter K C; Harris A L
Neoplastic stroma and epithelium show up-regulation of platelet-derived endothelial cell growth factor/thymidine phosphorylase in colorectal carcinomas but not adenomas.
Angiogenesis 1998;2(1):49-55.
1998: Harris A L
Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;152():341-52.
1998: Spataro V; Norbury C; Harris A L
The ubiquitin-proteasome pathway in cancer.
British journal of cancer 1998;77(3):448-55.
1998: Bui T D; O'Brien T; Crew J; Cranston D; Harris A L
High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer.
British journal of cancer 1998;77(2):319-24.
1997: Giatromanolaki A; Koukourakis M I; Theodossiou D; Barbatis K; O'Byrne K; Harris A L; Gatter K C
Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2485-92.
1997: Jaggar R T; Chan H Y; Harris A L; Bicknell R
Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery.
Human gene therapy 1997;8(18):2239-47.
1997: Koukourakis M I; Giatromanolaki A; O'Byrne K J; Whitehouse R M; Talbot D C; Gatter K C; Harris A L
Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer.
International journal of cancer. Journal international du cancer 1997;74(6):565-70.
1997: Saunders M P; Salisbury A J; O'Byrne K J; Long L; Whitehouse R M; Talbot D C; Mawer E B; Harris A L
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors.
The Journal of clinical endocrinology and metabolism 1997;82(12):4044-8.
1997: Crew J P; O'Brien T; Bradburn M; Fuggle S; Bicknell R; Cranston D; Harris A L
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
Cancer research 1997;57(23):5281-5.
1997: Saunders M P; Salisbury A J; O'Byrne K J; Souliotis V L; Varcoe S M; Talbot D C; Kyrtopoulos S A; Harris A L
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Anticancer research 1997;17(6D):4677-80.
1997: Spataro V; Toda T; Craig R; Seeger M; Dubiel W; Harris A L; Norbury C
Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit.
The Journal of biological chemistry 1997;272(48):30470-5.
1997: Bui T D; Tortora G; Ciardiello F; Harris A L
Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A.
Biochemical and biophysical research communications 1997;239(3):911-7.
1997: Bui T D; Beier D R; Jonssen M; Smith K; Dorrington S M; Kaklamanis L; Kearney L; Regan R; Sussman D J; Harris A L
cDNA cloning of a human dishevelled DVL-3 gene, mapping to 3q27, and expression in human breast and colon carcinomas.
Biochemical and biophysical research communications 1997;239(2):510-6.
1997: Engels K; Fox S B; Whitehouse R M; Gatter K C; Harris A L
Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
The Journal of pathology 1997;182(4):414-20.
1997: Maxwell P H; Dachs G U; Gleadle J M; Nicholls L G; Harris A L; Stratford I J; Hankinson O; Pugh C W; Ratcliffe P J
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(15):8104-9.
1997: Harris A L
Antiangiogenesis for cancer therapy.
Lancet 1997;349 Suppl 2():SII13-5.
1997: Kakolyris S; Kaklamanis L; Engels K; Turley H; Hickson I D; Gatter K C; Harris A L
Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence.
Cancer research 1997;57(9):1794-7.
1997: Fox S B; Harris A L
The epidermal growth factor receptor in breast cancer.
Journal of mammary gland biology and neoplasia 1997;2(2):131-41.
1997: Bui T D; Lako M; Lejeune S; Curtis A R; Strachan T; Lindsay S; Harris A L
Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25.
Gene 1997;189(1):25-9.
1997: Braybrooke J P; O'Byrne K J; Saunders M P; Propper D J; Salisbury A J; Boardman P; Taylor M; Ganesan T S; Talbot D C; Harris A L
A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(3):294-6.
1997: Fox S B; Engels K; Comley M; Whitehouse R M; Turley H; Gatter K C; Harris A L
Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(3):271-5.
1997: Bui T D; Rankin J; Smith K; Huguet E L; Ruben S; Strachan T; Harris A L; Lindsay S
A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas.
Oncogene 1997;14(10):1249-53.
1997: Scott P A; Smith K; Bicknel R; Harris A L
A reliable external control for ribonuclease protection assays.
Nucleic acids research 1997;25(6):1305-6.
1997: Relf M; LeJeune S; Scott P A; Fox S; Smith K; Leek R; Moghaddam A; Whitehouse R; Bicknell R; Harris A L
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Cancer research 1997;57(5):963-9.
1997: Engels K; Fox S B; Whitehouse R M; Gatter K C; Harris A L
Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast.
The Journal of pathology 1997;181(2):207-12.
1997: Giatromanolaki A; Koukourakis M I; Comley M; Kaklamanis L; Turley H; O'Byrne K; Harris A L; Gatter K C
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer.
The Journal of pathology 1997;181(2):196-9.
1997: O'Brien T; Cranston D; Fuggle S; Bicknell R; Harris A L
Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer.
Cancer research 1997;57(1):136-40.
1997: Patterson A V; Saunders M P; Chinje E C; Talbot D C; Harris A L; Strafford I J
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
British journal of cancer 1997;76(10):1338-47.
1997: Fox S B; Harris A L
Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.
Investigational new drugs 1997;15(1):15-28.
1997: Turley H; Comley M; Houlbrook S; Nozaki N; Kikuchi A; Hickson I D; Gatter K; Harris A L
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
British journal of cancer 1997;75(9):1340-6.
1997: Bui T D; Zhang L; Rees M C; Bicknell R; Harris A L
Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma.
British journal of cancer 1997;75(8):1131-6.
1997: Davies S L; Bergh J; Harris A L; Hickson I D
Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
British journal of cancer 1997;75(6):816-21.
1997: Koukourakis M I; Giatromanolaki A; O'Byrne K J; Comley M; Whitehouse R M; Talbot D C; Gatter K C; Harris A L
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.
British journal of cancer 1997;75(4):477-81.
1997: Engels K; Fox S B; Harris A L
Angiogenesis as a biologic and prognostic indicator in human breast carcinoma.
EXS 1997;79():113-56.
1996: Giatromanolaki A; Koukourakis M I; O'Byrne K; Kaklamanis L; Dicoglou C; Trichia E; Whitehouse R; Harris A L; Gatter K C
Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis.
Anticancer research 1996;16(6B):3819-25.
1996: Sandri M I; Isaacs R J; Ongkeko W M; Harris A L; Hickson I D; Broggini M; Vikhanskaya F
p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.
Nucleic acids research 1996;24(22):4464-70.
1996: Kaklamanis L; Koukourakis M I; Leek R; Giatromanolaki A; Ritter M; Whitehouse R; Gatter K C; Harris A L
Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance.
British journal of cancer 1996;74(10):1627-31.
1996: O'Brien T S; Fox S B; Dickinson A J; Turley H; Westwood M; Moghaddam A; Gatter K C; Bicknell R; Harris A L
Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers.
Cancer research 1996;56(20):4799-804.
1996: Leek R D; Lewis C E; Whitehouse R; Greenall M; Clarke J; Harris A L
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.
Cancer research 1996;56(20):4625-9.
1996: Fox S B; Gatter K C; Harris A L
Tumour angiogenesis.
The Journal of pathology 1996;179(3):232-7.
1996: Houlbrook S; Harris A L; Carmichael J; Stratford I J
Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.
Anticancer research 1996;16(4A):1603-10.
1996: Isaacs R J; Harris A L; Hickson I D
Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells.
The Journal of biological chemistry 1996;271(28):16741-7.
1996: Crew J P; O'Brien T S; Harris A L
Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.
Cancer metastasis reviews 1996;15(2):221-30.
1996: Sandri M I; Hochhauser D; Ayton P; Camplejohn R C; Whitehouse R; Turley H; Gatter K; Hickson I D; Harris A L
Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.
British journal of cancer 1996;73(12):1518-24.
1996: O'Brien T; Cranston D; Fuggle S; Bicknell R; Harris A L
The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers.
Cancer research 1996;56(11):2515-8.
1996: Giatromanolaki A; Koukourakis M; O'Byrne K; Fox S; Whitehouse R; Talbot D C; Harris A L; Gatter K C
Prognostic value of angiogenesis in operable non-small cell lung cancer.
The Journal of pathology 1996;179(1):80-8.
1996: Kaklamanis L; Savage A; Mortensen N; Tsiotos P; Doussis-Anagnostopoulou I; Biddolph S; Whitehouse R; Harris A L; Gatter K C
Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia.
The Journal of pathology 1996;179(1):10-4.
1996: Thompson C H; Macaulay V M; O'Byrne K J; Kemp G J; Wilner S M; Talbot D C; Harris A L; Radda G K
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
British journal of cancer 1996;73(10):1161-5.
1996: Philip P A; Souliotis V L; Harris A L; Salisbury A; Tates A D; Mitchell K; van Delft J H; Ganesan T S; Kyrtopoulos S A
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):303-10.
1996: Fox S B; Westwood M; Moghaddam A; Comley M; Turley H; Whitehouse R M; Bicknell R; Gatter K C; Harris A L
The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium.
British journal of cancer 1996;73(3):275-80.
1996: Bicknell R; Harris A L
Mechanisms and therapeutic implications of angiogenesis.
Current opinion in oncology 1996;8(1):60-5.
1996: Carmichael J; Fink U; Russell R C; Spittle M F; Harris A L; Spiessi G; Blatter J
Phase II study of gemcitabine in patients with advanced pancreatic cancer.
British journal of cancer 1996;73(1):101-5.
1996: Korkolopoulou P; Kaklamanis L; Pezzella F; Harris A L; Gatter K C
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
British journal of cancer 1996;73(2):148-53.
1996: Harris A L; Zhang H; Moghaddam A; Fox S; Scott P; Pattison A; Gatter K; Stratford I; Bicknell R
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Breast cancer research and treatment 1996;38(1):97-108.
1995: Fox S B; Turner G D; Gatter K C; Harris A L
The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium.
The Journal of pathology 1995;177(4):369-76.
1995: O'Brien T S; Harris A L
Angiogenesis in urological malignancy.
British journal of urology 1995;76(6):675-82.
1995: Houlbrook S; Addison C M; Davies S L; Carmichael J; Stratford I J; Harris A L; Hickson I D
Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
British journal of cancer 1995;72(6):1454-61.
1995: Turley H; Pezzella F; Kocialkowski S; Comley M; Kaklamanis L; Fawcett J; Simmons D; Harris A L; Gatter K C
The distribution of the deleted in colon cancer (DCC) protein in human tissues.
Cancer research 1995;55(23):5628-31.
1995: Fox S B; Leek R D; Weekes M P; Whitehouse R M; Gatter K C; Harris A L
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.
The Journal of pathology 1995;177(3):275-83.
1995: Kaklamanis L; Leek R; Koukourakis M; Gatter K C; Harris A L
Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.
Cancer research 1995;55(22):5191-4.
1995: Patterson A V; Barham H M; Chinje E C; Adams G E; Harris A L; Stratford I J
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
British journal of cancer 1995;72(5):1144-50.
1995: Hickman P F; Kemp G J; Thompson C H; Salisbury A J; Wade K; Harris A L; Radda G K
Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study.
British journal of cancer 1995;72(4):998-1003.
1995: Patterson A V; Zhang H; Moghaddam A; Bicknell R; Talbot D C; Stratford I J; Harris A L
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
British journal of cancer 1995;72(3):669-75.
1995: O'Brien T S; Smith K; Cranston D; Fuggle S; Bicknell R; Harris A L
Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy.
British journal of urology 1995;76(3):311-4.
1995: Ongkeko W; Ferguson D J; Harris A L; Norbury C
Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage.
Journal of cell science 1995;108 ( Pt 8)():2897-904.
1995: Dickinson A J; Fox S B; Newcomb P V; Persad R A; Sibley G N; Harris A L
An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
The Journal of urology 1995;154(1):237-41.
1995: Fox S B; Moghaddam A; Westwood M; Turley H; Bicknell R; Gatter K C; Harris A L
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
The Journal of pathology 1995;176(2):183-90.
1995: Huguet E L; Smith K; Bicknell R; Harris A L
Regulation of Wnt5a mRNA expression in human mammary epithelial cells by cell shape, confluence, and hepatocyte growth factor.
The Journal of biological chemistry 1995;270(21):12851-6.
1995: Isaacs R J; Davies S L; Wells N J; Harris A L
Topoisomerases II alpha and beta as therapy targets in breast cancer.
Anti-cancer drugs 1995;6(2):195-211.
1995: Lejeune S; Huguet E L; Hamby A; Poulsom R; Harris A L
Wnt5a cloning, expression, and up-regulation in human primary breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):215-22.
1995: Zhang H T; Craft P; Scott P A; Ziche M; Weich H A; Harris A L; Bicknell R
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.
Journal of the National Cancer Institute 1995;87(3):213-9.
1995: Moghaddam A; Zhang H T; Fan T P; Hu D E; Lees V C; Turley H; Fox S B; Gatter K C; Harris A L; Bicknell R
Thymidine phosphorylase is angiogenic and promotes tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(4):998-1002.
1995: O'Brien T; Cranston D; Fuggle S; Bicknell R; Harris A L
Different angiogenic pathways characterize superficial and invasive bladder cancer.
Cancer research 1995;55(3):510-3.
1995: Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies S L; North P; Harris A L; Hickson I D
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):49-56.
1995: Fox S B; Turner G D; Leek R D; Whitehouse R M; Gatter K C; Harris A L
The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium.
Breast cancer research and treatment 1995;36(2):219-26.
1995: Harris A L; Fox S; Leek R; Zhang H; Scott P; Bicknell R; Gatter K
Breast cancer angiogenesis: therapy target and prognostic factor.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):831-2.
1995: Carmichael J; Philip P A; Forfar C; Harris A L
An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.
Cancer chemotherapy and pharmacology 1995;37(1-2):134-8.
1994: Dickinson A J; Fox S B; Persad R A; Hollyer J; Sibley G N; Harris A L
Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas.
British journal of urology 1994;74(6):762-6.
1994: Walker L J; Craig R B; Harris A L; Hickson I D
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress.
Nucleic acids research 1994;22(23):4884-9.
1994: Scott P A; Harris A L
Current approaches to targeting cancer using antiangiogenesis therapies.
Cancer treatment reviews 1994;20(4):393-412.
1994: Kaklamanis L; Townsend A; Doussis-Anagnostopoulou I A; Mortensen N; Harris A L; Gatter K C
Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.
The American journal of pathology 1994;145(3):505-9.
1994: Harris A L; Fox S; Bicknell R; Leek R; Relf M; LeJeune S; Kaklamanis L
Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer.
Cancer 1994;74(3 Suppl):1021-5.
1994: Fox S B; Fawcett J; Jackson D G; Collins I; Gatter K C; Harris A L; Gearing A; Simmons D L
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms.
Cancer research 1994;54(16):4539-46.
1994: Reynolds K; Farzaneh F; Collins W P; Campbell S; Bourne T H; Lawton F; Moghaddam A; Harris A L; Bicknell R
Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor.
Journal of the National Cancer Institute 1994;86(16):1234-8.
1994: North P S; Davies S L; Ciardiello F; Damiano V; Bianco C; Pepe S; Bianco A R; Harris A L; Hickson I D; Tortora G
Overexpression of the RI alpha subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3'5'-monophosphate in Chinese hamster ovary cells.
Cancer research 1994;54(15):4123-8.
1994: Kirk J; Syed S K; Harris A L; Jarman M; Roufogalis B D; Stratford I J; Carmichael J
Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.
Biochemical pharmacology 1994;48(2):277-85.
1994: Kirk J; Carmichael J; Stratford I J; Harris A L
Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.
British journal of cancer 1994;69(6):988-94.
1994: Patterson A V; Robertson N; Houlbrook S; Stephens M A; Adams G E; Harris A L; Stratford I J; Carmichael J
The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
International journal of radiation oncology, biology, physics 1994;29(2):369-72.
1994: Huguet E L; McMahon J A; McMahon A P; Bicknell R; Harris A L
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue.
Cancer research 1994;54(10):2615-21.
1994: Braddock P S; Hu D E; Fan T P; Stratford I J; Harris A L; Bicknell R
A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.
British journal of cancer 1994;69(5):890-8.
1994: Craft P S; Harris A L
Clinical prognostic significance of tumour angiogenesis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):305-11.
1994: Leek R D; Kaklamanis L; Pezzella F; Gatter K C; Harris A L
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
British journal of cancer 1994;69(1):135-9.
1994: Fox S B; Smith K; Hollyer J; Greenall M; Hastrich D; Harris A L
The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.
Breast cancer research and treatment 1994;29(1):41-9.
1994: Dixon J; Kaklamanis L; Turley H; Hickson I D; Leek R D; Harris A L; Gatter K C
Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin.
Journal of clinical pathology 1994;47(1):43-7.
1994: Fox S B; Leek R D; Smith K; Hollyer J; Greenall M; Harris A L
Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival.
Breast cancer research and treatment 1994;29(1):109-16.
1994: Philip P A; Carmichael J; Tonkin K; Ganesan T A; Harris A L
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1027-9.
1993: Toi M; Harris A L; Bicknell R
cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo.
British journal of cancer 1993;68(6):1088-96.
1993: Horak E R; Harris A L; Stuart N; Bicknell R
Angiogenesis in breast cancer. Regulation, prognostic aspects, and implications for novel treatment strategies.
Annals of the New York Academy of Sciences 1993;698():71-84.
1993: Fox S B; Gatter K C; Bicknell R; Going J J; Stanton P; Cooke T G; Harris A L
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer.
Cancer research 1993;53(18):4161-3.
1993: LeJeune S; Leek R; Horak E; Plowman G; Greenall M; Harris A L
Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer.
Cancer research 1993;53(15):3597-602.
1993: O'Sullivan C; Lewis C E; Harris A L; McGee J O
Secretion of epidermal growth factor by macrophages associated with breast carcinoma.
Lancet 1993;342(8864):148-9.
1993: Kirk J; Houlbrook S; Stuart N S; Stratford I J; Harris A L; Carmichael J
Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.
British journal of cancer 1993;67(6):1189-95.
1993: Millward M J; Cantwell B M; Munro N C; Robinson A; Corris P A; Harris A L
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
British journal of cancer 1993;67(5):1031-5.
1993: Philip P A; Kaklamanis L; Carmichael J; Tonkin K; Morrison H; Gatter K; Harris A L
The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
British journal of cancer 1993;67(4):644-9.
1993: Hochhauser D; Harris A L
The role of topoisomerase II alpha and beta in drug resistance.
Cancer treatment reviews 1993;19(2):181-94.
1993: Smith K; Houlbrook S; Greenall M; Carmichael J; Harris A L
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Oncogene 1993;8(4):933-8.
1993: Philip P A; Carmichael J; Tonkin K; Buamah P K; Britton J; Dowsett M; Harris A L
Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
British journal of cancer 1993;67(2):379-82.
1993: Pezzella F; Morrison H; Jones M; Gatter K C; Lane D; Harris A L; Mason D Y
Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma.
Histopathology 1993;22(1):39-44.
1993: Kaklamanis L; Gatter K C; Mortensen N; Baigrie R J; Heryet A; Lane D P; Harris A L
p53 expression in colorectal adenomas.
The American journal of pathology 1993;142(1):87-93.
1993: Kirk J; Houlbrook S; Stuart N S; Stratford I J; Harris A L; Carmichael J
Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1152-7.
1993: Sacks N P; Smith K; Norman A P; Greenall M; LeJeune S; Harris A L
Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):426-8.
1993: Harris A L; Horak E
Growth factors and angiogenesis in breast cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;127():35-41.
1992: Stuart N S; Philip P; Harris A L; Tonkin K; Houlbrook S; Kirk J; Lien E A; Carmichael J
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.
British journal of cancer 1992;66(5):833-9.
1992: Jenkins J R; Ayton P; Jones T; Davies S L; Simmons D L; Harris A L; Sheer D; Hickson I D
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.
Nucleic acids research 1992;20(21):5587-92.
1992: Horak E R; Leek R; Klenk N; LeJeune S; Smith K; Stuart N; Greenall M; Stepniewska K; Harris A L
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.
Lancet 1992;340(8828):1120-4.
1992: Kaklamanis L; Gatter K C; Mortensen N; Harris A L
Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer.
British journal of cancer 1992;66(4):712-6.
1992: Denton K J; Stretch J R; Gatter K C; Harris A L
A study of adhesion molecules as markers of progression in malignant melanoma.
The Journal of pathology 1992;167(2):187-91.
1992: Kaklamanis L; Gatter K C; Hill A B; Mortensen N; Harris A L; Krausa P; McMichael A; Bodmer J G; Bodmer W F
Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer.
International journal of cancer. Journal international du cancer 1992;51(3):379-85.
1992: Lind M J; Cantwell B M; Millward M J; Robinson A; Proctor M; Simmons D; Carmichael J; Harris A L
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
British journal of cancer 1992;65(4):621-3.
1992: Philip P A; Joel S; Monkman S C; Dolega-Ossowski E; Tonkin K; Carmichael J; Idle J R; Harris A L
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.
British journal of cancer 1992;65(2):267-70.
1992: Kuzu I; Bicknell R; Harris A L; Jones M; Gatter K C; Mason D Y
Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours.
Journal of clinical pathology 1992;45(2):143-8.
1992: Wright C; Cairns J; Cantwell B J; Cattan A R; Hall A G; Harris A L; Horne C H
Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases.
British journal of cancer 1992;65(2):271-4.
1992: Hoban P R; Robson C N; Davies S M; Hall A G; Cattan A R; Hickson I D; Harris A L
Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C.
Biochemical pharmacology 1992;43(4):685-93.
1992: Toi M; Bicknell R; Harris A L
Inhibition of colon and breast carcinoma cell growth by interleukin-4.
Cancer research 1992;52(2):275-9.
1992: Cairns J; Wright C; Cattan A R; Hall A G; Cantwell B J; Harris A L; Horne C H
Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas.
The Journal of pathology 1992;166(1):19-25.
1992: Wright C; Nicholson S; Angus B; Sainsbury J R; Farndon J; Cairns J; Harris A L; Horne C H
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
British journal of cancer 1992;65(1):118-21.
1992: Harris A L; Nicholson S; Sainsbury R; Wright C; Farndon J
Epidermal growth factor receptor and other oncogenes as prognostic markers.
Journal of the National Cancer Institute. Monographs 1992;(11):181-7.
1992: Millward M J; Cantwell B M; Lien E A; Carmichael J; Harris A L
Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):805-10.
1992: Harris A L
p53 expression in human breast cancer.
Advances in cancer research 1992;59():69-88.
1992: Harris A L; Hochhauser D
Mechanisms of multidrug resistance in cancer treatment.
Acta oncologica (Stockholm, Sweden) 1992;31(2):205-13.
1991: Horak E; Smith K; Bromley L; LeJeune S; Greenall M; Lane D; Harris A L
Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.
Oncogene 1991;6(12):2277-84.
1991: Fry A M; Chresta C M; Davies S M; Walker M C; Harris A L; Hartley J A; Masters J R; Hickson I D
Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Cancer research 1991;51(24):6592-5.
1991: Stretch J R; Gatter K C; Ralfkiaer E; Lane D P; Harris A L
Expression of mutant p53 in melanoma.
Cancer research 1991;51(21):5976-9.
1991: Moorghen M; Ince P; Finney K J; Watson A J; Harris A L
Organ culture as a model for investigating the effects of antimetabolites and nucleoside transport inhibitors on rodent colonic mucosa.
In vitro cellular & developmental biology : journal of the Tissue Culture Association 1991;27A(11):873-7.
1991: Nutt J E; Harris A L; Lunec J
Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.
British journal of cancer 1991;64(4):671-6.
1991: Curtin N J; Harris A L; Aherne G W
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Cancer research 1991;51(9):2346-52.
1991: Millward M J; Cantwell B M; Dowsett M; Carmichael J; Harris A L
Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
British journal of cancer 1991;63(5):763-4.
1991: Ince P; Elliott K; Appleton D R; Moorghen M; Finney K J; Sunter J P; Harris A L; Watson A J
Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture.
Biochemical pharmacology 1991;41(8):1217-25.
1991: Harris A L
Growth factors and receptors in cancer.
Current opinion in biotechnology 1991;2(2):260-8.
1991: Gullick W J; Love S B; Wright C; Barnes D M; Gusterson B; Harris A L; Altman D G
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
British journal of cancer 1991;63(3):434-8.
1991: Toi M; Harris A L; Bicknell R
Interleukin-4 is a potent mitogen for capillary endothelium.
Biochemical and biophysical research communications 1991;174(3):1287-93.
1991: Hendrick A M; Harris A L; Cantwell B M
Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(1):71-2.
1991: Fawcett J; Harris A L; Bicknell R
Isolation and properties in culture of human adrenal capillary endothelial cells.
Biochemical and biophysical research communications 1991;174(2):903-8.
1991: Moorghen M; Cairns J; Forrester L M; Hayes J D; Hall A; Cattan A R; Wolf C R; Harris A L
Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa.
Carcinogenesis 1991;12(1):13-7.
1991: Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon J R; Harris A L
Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
British journal of cancer 1991;63(1):146-50.
1991: Tungekar M F; Turley H; Dunnill M S; Gatter K C; Ritter M A; Harris A L
Interleukin 4 receptor expression on human lung tumors and normal lung.
Cancer research 1991;51(1):261-4.
1991: Hochhauser D; Harris A L
Drug resistance.
British medical bulletin 1991;47(1):178-96.
1991: Bicknell R; Harris A L
Novel growth regulatory factors and tumour angiogenesis.
European journal of cancer (Oxford, England : 1990) 1991;27(6):781-5.
1990: Nicholson S; Wright C; Sainsbury J R; Halcrow P; Kelly P; Angus B; Farndon J R; Harris A L
Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.
The Journal of steroid biochemistry and molecular biology 1990;37(6):811-4.
1990: Forrester L M; Hayes J D; Millis R; Barnes D; Harris A L; Schlager J J; Powis G; Wolf C R
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue.
Carcinogenesis 1990;11(12):2163-70.
1990: Chatterjee M; Harris A L
Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein.
British journal of cancer 1990;62(5):712-7.
1990: Hoban P R; Walton M I; Robson C N; Godden J; Stratford I J; Workman P; Harris A L; Hickson I D
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions.
Cancer research 1990;50(15):4692-7.
1990: Millward M J; Harris A L; Cantwell B M
Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer.
Cancer 1990;65(11):2421-5.
1990: Moorghen M; Ince P; Finney K J; Watson A J; Harris A L
Epidermal growth factor receptors in colorectal carcinoma.
Anticancer research 1990;10(3):605-11.
1990: Chatterjee M; Robson C N; Harris A L
Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines.
Cancer research 1990;50(9):2818-22.
1990: Neal D E; Sharples L; Smith K; Fennelly J; Hall R R; Harris A L
The epidermal growth factor receptor and the prognosis of bladder cancer.
Cancer 1990;65(7):1619-25.
1990: Chatterjee M; Harris A L
Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein.
European journal of cancer (Oxford, England : 1990) 1990;26(4):432-6.
1990: Moses K; Willmore E; Harris A L; Durkacz B W
Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide.
Cancer research 1990;50(7):1992-6.
1990: Carmichael J; Cantwell B M; Mannix K A; Veale D; Elford H L; Blackie R; Kerr D J; Kaye S B; Harris A L
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.
British journal of cancer 1990;61(3):447-50.
1990: Henry J A; McCarthy A L; Angus B; Westley B R; May F E; Nicholson S; Cairns J; Harris A L; Horne C H
Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study.
Cancer 1990;65(2):265-71.
1990: Harris A L; Cantwell B M; Carmichael J; Wilson R; Farndon J; Dawes P; Ghani S; Evans R G
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer.
Lancet 1990;335(8683):186-90.
1990: Carmichael J; Cantwell B M; Harris A L; Buamah P K; Hodson A W; Skillen A W
Assessment of renal toxicity by urinary enzymes in patients receiving chemotherapy with 8-methyl-8-acetylenic-putrescine.
Cancer chemotherapy and pharmacology 1990;26(1):65-6.
1989: Hall A; Robson C N; Hickson I D; Harris A L; Proctor S J; Cattan A R
Possible role of inhibition of glutathione S-transferase in the partial reversal of chlorambucil resistance by indomethacin in a Chinese hamster ovary cell line.
Cancer research 1989;49(22):6265-8.
1989: Smith K; Fennelly J A; Neal D E; Hall R R; Harris A L
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors.
Cancer research 1989;49(21):5810-5.
1989: Lennard T W; Harris A L; Hales J; Dickinson A; Wolstencroft R; Halcrow P; Shenton B K; McDonald M; Lawrence G F; Taylor R M
A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246738).
European journal of cancer & clinical oncology 1989;25(11):1571-6.
1989: Curtin N J; Newell D R; Harris A L
Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.
Biochemical pharmacology 1989;38(19):3281-8.
1989: Lewis A D; Forrester L M; Hayes J D; Wareing C J; Carmichael J; Harris A L; Mooghen M; Wolf C R
Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines.
British journal of cancer 1989;60(3):327-31.
1989: Mannix K A; Carmichael J; Harris A L; Cantwell B M
Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Cancer 1989;64(6):1358-61.
1989: Davies S M; Davies S L; Harris A L; Hickson I D
Isolation of two Chinese hamster ovary cell mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides.
Cancer research 1989;49(16):4526-30.
1989: Smith K; Miller W R; Fennelly J A; Matthews J N; Scott W N; Harris A L
Quantification of epidermal growth factor in human breast cyst fluids: correlation with dehydroepiandrosterone-sulphate and electrolyte concentrations.
International journal of cancer. Journal international du cancer 1989;44(2):229-32.
1989: Harris A L; Cantwell B M; Carmichael J; Dawes P; Robinson A; Farndon J; Wilson R
Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
European journal of cancer & clinical oncology 1989;25(7):1105-11.
1989: Cantwell B M; Carmichael J; Mannix K A; Harris A L
Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy.
European journal of cancer & clinical oncology 1989;25(5):917-8.
1989: Carmichael J; Cantwell B M; Harris A L
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
European journal of cancer & clinical oncology 1989;25(5):911-2.
1989: Wright C; Angus B; Nicholson S; Sainsbury J R; Cairns J; Gullick W J; Kelly P; Harris A L; Horne C H
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Cancer research 1989;49(8):2087-90.
1989: Edwards C M; Carmichael J; Baylis P H; Harris A L
Arginine vasopressin--a mediator of chemotherapy induced emesis?
British journal of cancer 1989;59(3):467-70.
1989: Neal D E; Smith K; Fennelly J A; Bennett M K; Hall R R; Harris A L
Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding.
The Journal of urology 1989;141(3):517-21.
1989: Robson C N; Harris A L; Hickson I D
Defective repair of DNA single- and double-strand breaks in the bleomycin- and X-ray-sensitive Chinese hamster ovary cell mutant, BLM-2.
Mutation research 1989;217(2):93-100.
1989: Davies S M; Harris A L; Hickson I D
Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.
Nucleic acids research 1989;17(4):1337-51.
1989: Harris A L; Carmichael J; Cantwell B M; Dowsett M
Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
British journal of cancer 1989;59(1):97-9.
1989: Nicholson S; Sainsbury J R; Halcrow P; Chambers P; Farndon J R; Harris A L
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Lancet 1989;1(8631):182-5.
1989: Harris A L; Nicholson S; Sainsbury J R; Farndon J; Wright C
Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
Journal of steroid biochemistry 1989;34(1-6):123-31.
1989: Carmichael J; Cantwell B M; Edwards C M; Zussman B D; Thompson S; Rapeport W G; Harris A L
A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Cancer chemotherapy and pharmacology 1989;24(1):45-9.
1989: Cantwell B M; Veale D; Rivett C; Ghani S; Harris A L
Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1989;23(4):252-4.
1989: Harris A L; Carmichael J; Cantwell B M; Dowsett M
Zoladex: therapeutic effects in postmenopausal breast cancer.
Hormone research 1989;32 Suppl 1():213-6; discussion 217.
1989: Harris A L
Epidermal growth factor receptor in human breast cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;113():70-7.
1988: Nicholson S; Halcrow P; Sainsbury J R; Angus B; Chambers P; Farndon J R; Harris A L
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
British journal of cancer 1988;58(6):810-4.
1988: Lewis A D; Hickson I D; Robson C N; Harris A L; Hayes J D; Griffiths S A; Manson M M; Hall A E; Moss J E; Wolf C R
Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(22):8511-5.
1988: Needham G K; Nicholson S; Angus B; Farndon J R; Harris A L
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Cancer research 1988;48(22):6603-7.
1988: Cantwell B M; Mannix K A; Roberts J T; Ghani S E; Harris A L
Thromboembolic events during combination chemotherapy for germ cell-malignancy.
Lancet 1988;2(8619):1086-7.
1988: Sainsbury J R; Nicholson S; Angus B; Farndon J R; Malcolm A J; Harris A L
Epidermal growth factor receptor status of histological sub-types of breast cancer.
British journal of cancer 1988;58(4):458-60.
1988: Moses K; Harris A L; Durkacz B W
Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors.
Cancer research 1988;48(20):5650-4.
1988: Harris A L; Cantwell B M; Dowsett M
High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
British journal of cancer 1988;58(4):493-6.
1988: Cantwell B M; Harris A L
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
British journal of cancer 1988;58(2):189-90.
1988: Cantwell B M; Carmichael J; Ghani S E; Harris A L
Thromboses and thromboemboli in patients with lymphoma during cytotoxic chemotherapy.
BMJ (Clinical research ed.) 1988;297(6642):179-80.
1988: Nicholson S; Sainsbury J R; Needham G K; Chambers P; Farndon J R; Harris A L
Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance.
International journal of cancer. Journal international du cancer 1988;42(1):36-41.
1988: Carmichael J; Cantwell B M; Edwards C M; Rapeport W G; Harris A L
The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
BMJ (Clinical research ed.) 1988;297(6641):110-1.
1988: Hendrick A M; Mitchell M D; Harris A L
Plasma prostaglandins in lung cancer.
European journal of cancer & clinical oncology 1988;24(6):1069-71.
1988: Curtin N J; Harris A L
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Biochemical pharmacology 1988;37(11):2113-20.
1988: Horne G M; Angus B; Wright C; Needham G; Nicholson S; Harris A L; Innes B; Horne C H
Relationships between oestrogen receptor,epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer.
The Journal of pathology 1988;155(2):143-50.
1988: Moses K; Harris A L; Durkacz B W
Adenosine-diphosphoribosyltransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs.
Biochemical pharmacology 1988;37(11):2155-60.
1988: Cantwell B M; Macaulay V; Harris A L; Kaye S B; Smith I E; Milsted R A; Calvert A H
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.
European journal of cancer & clinical oncology 1988;24(4):733-6.
1988: Robson C N; Hall A; Harris A L; Hickson I D
Bleomycin and X-ray-hypersensitive Chinese hamster ovary cell mutants: genetic analysis and cross-resistance to neocarzinostatin.
Mutation research 1988;193(2):157-65.
1988: Cantwell B M; Bozzino J M; Corris P; Harris A L
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
European journal of cancer & clinical oncology 1988;24(2):123-9.
1988: Lunn J M; Harris A L
Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.
British journal of cancer 1988;57(1):54-8.
1988: Cantwell B M; Carmichael J; Ghani S; Harris A L
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cancer chemotherapy and pharmacology 1988;21(1):49-52.
1988: Skillen A W; Buamah P K; Cantwell B M; Cornell C; Hodson A W; Harris A L
Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Cancer chemotherapy and pharmacology 1988;22(3):228-34.
1987: Robson C N; Lewis A D; Wolf C R; Hayes J D; Hall A; Proctor S J; Harris A L; Hickson I D
Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity.
Cancer research 1987;47(22):6022-7.
1987: Sainsbury J R; Farndon J R; Needham G K; Malcolm A J; Harris A L
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
Lancet 1987;1(8547):1398-402.
1987: Robson C N; Hoban P R; Harris A L; Hickson I D
Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Cancer research 1987;47(6):1560-5.
1987: Cantwell B M; Mannix K A; Harris A L
Back pain--a presentation of metastatic testicular germ cell tumours.
Lancet 1987;1(8527):262-4.
1986: Harris A L; Cantwell B M; Sainsbury J R; Needham G; Evans R G; Dawes P J; Wilson R; Farndon J
Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Breast cancer research and treatment 1986;7 Suppl():S41-4.
1986: Harris A L; Dowsett M; Cantwell B M; Sainsbury J R; Needham G; Farndon J; Wilson R
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Breast cancer research and treatment 1986;7 Suppl():S69-72.

Sign-in to see more